Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 15/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25600525 | 0.97 | OPRL1 (0.34) | OPRL1OPRM1HRH3OPRK1OPRD1 | |
| SCHEMBL25600526 | 0.94 | OPRL1 (0.34) | OPRL1OPRM1HRH3OPRK1OPRD1 | |
| SCHEMBL25600508 | 0.93 | HRH3 (0.34) | OPRL1OPRM1HRH3OPRK1OPRD1 | |
| SCHEMBL25600338 | 0.92 | OPRL1 (0.33) | OPRL1OPRM1HRH3CHRM1CHRM4 | |
| SCHEMBL25600527 | 0.92 | OPRL1 (0.38) | OPRL1OPRM1HRH3OPRK1OPRD1 | |
| SCHEMBL25600528 | 0.92 | HRH3 (0.37) | OPRL1OPRM1HRH3OPRK1OPRD1 | |
| SCHEMBL25600504 | 0.89 | OPRL1 (0.34) | OPRL1OPRM1HRH3OPRK1OPRD1 | |
| SCHEMBL25600507 | 0.89 | OPRL1 (0.34) | OPRL1OPRM1HRH3OPRK1OPRD1 | |
| SCHEMBL25605727 | 0.87 | ALDH1A1 (0.41) | HRH3CHRM1CHRM2KCNH2 | |
| SCHEMBL25600524 | 0.86 | POLB (0.38) | OPRL1OPRM1HRH3OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | OPRL1 4834/4885OPRM1 4706/4885HRH3 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.